[HTML][HTML] Principles and recommendations for incorporating estimands into clinical study protocol templates

H Lynggaard, J Bell, C Lösch, A Besseghir, K Rantell… - Trials, 2022 - Springer
Clinical study protocols are the foundation of good clinical studies. Prospective and
multidisciplinary collaboration that pays attention to the design of all components of the study …

Preservation of lymphopoietic potential and virus suppressive capacity by CD8+ T cells in HIV-2–infected controllers

…, C Bayard, CD Muylder, A Besseghir… - The Journal of …, 2016 - journals.aai.org
Compared with HIV-1, HIV-2 infection is characterized by a larger proportion of slow or
nonprogressors. A better understanding of HIV-2 pathogenesis should open new therapeutic …

Week 96 efficacy of lopinavir/ritonavir monotherapy in virologically suppressed patients with HIV: a randomized non-inferiority trial (ANRS 140 DREAM)

…, L Morand-Joubert, A Besseghir… - Journal of …, 2018 - academic.oup.com
Background Sparing of antiretroviral drug classes could reduce the toxicity and cost of
maintenance treatment for HIV infection. Objectives To evaluate the non-inferiority of efficacy and …

One-year MR angiographic and clinical follow-up after intracranial mechanical thrombectomy using a stent retriever device

…, JC Ferré, JC Gentric, A Besseghir… - American Journal …, 2015 - Am Soc Neuroradiology
BACKGROUND AND PURPOSE: Little is known about the consequences of arterial wall
damage that may be due to mechanical endovascular thrombectomy. Our aim was to perform 1-…

First-line raltegravir/emtricitabine/tenofovir combination in human immunodeficiency virus type 2 (HIV-2) infection: a phase 2, noncomparative trial (ANRS 159 HIV-2)

…, D Descamps, S Gallien, A Besseghir… - Clinical Infectious …, 2018 - academic.oup.com
Background New options for first-line treatment of human immunodeficiency virus type 2 (HIV-2)
infection are needed. We evaluated an integrase inhibitor (raltegravir)–containing …

First line raltegravir/emtricitabine/tenofovir combination in HIV-2 infection: phase 2 non-comparative trial (ANRS 159 HIV-2)

…, D Descamps, S Gallien, A Besseghir… - Clinical Infectious …, 2018 - hal.science
Background: New options for first-line treatment of HIV-2 infection are needed. We evaluated
an integrase inhibitor (raltegravir)-containing regimen. Methods: ART-naive adults infected …

Cyclosporine A delivery to the eye: a pharmaceutical challenge

F Lallemand, O Felt-Baeyens, K Besseghir… - European Journal of …, 2003 - Elsevier
Systemic administration of cyclosporine A (CsA) is commonly used in the treatment of local
ophthalmic conditions involving cytokines, such as corneal graft rejection, autoimmune …

Inhibition of human immunodeficiency virus type 1 replication in human cells by Debio-025, a novel cyclophilin binding agent

…, JM Dumont, P Scalfaro, K Besseghir… - Antimicrobial agents …, 2008 - Am Soc Microbiol
Debio-025 is a synthetic cyclosporine with no immunosuppressive capacity but a high
inhibitory potency against cyclophilin A (CypA)-associated cis-trans prolyl isomerase (PPIase) …

The nonimmunosuppressive cyclosporin analogs NIM811 and UNIL025 display nanomolar potencies on permeability transition in brain-derived mitochondria

…, UT Ruegg, JM Dumont, K Besseghir… - Journal of bioenergetics …, 2004 - Springer
Cyclosporin A (CsA) is highly neuroprotective in several animal models of acute neurological
damage and neurodegenerative disease with inhibition of the mitochondrial permeability …

Neural tube defects after infertility treatment: a review

EE Wallach, K Van Loon, K Besseghir, A Eshkol - Fertility and sterility, 1992 - Elsevier
Objective To investigate whether an association exists between ovulation induction and
neural tube defects (NTDs). Materials and Methods Risk estimations in the medical literature …